Isomorphic Labs seeks funding at $40B valuation, sources say
Summary
Isomorphic Labs, an AI-powered drug discovery startup emerged from Alphabet’s Google DeepMind, is currently in discussions to secure new funding with a target valuation of at least $40 billion. This move underscores the growing trend of technology companies forming specialized spinouts to focus on innovative applications of AI in pharmaceutical research, which increasingly helps streamline the processes of compound identification and testing.
Tokens
$GOOGL
Analysis
Alphabet: Alphabet Inc. serves as the parent holding company for Google and its subsidiaries, including the AI research organization Google DeepMind. It maintains broad involvement in technology innovation across multiple sectors. Isomorphic Labs originated as a spinout from the DeepMind unit under Alphabet’s umbrella. Isomorphic Labs: Isomorphic Labs is an AI-powered drug discovery startup spun out of Alphabet’s Google DeepMind. The company applies advanced artificial intelligence techniques to accelerate the identification and development of new medicines. It is currently in early discussions regarding additional capital raising to advance its operations. AI in Drug Discovery: Artificial intelligence applications are increasingly integrated into pharmaceutical research to streamline compound identification and testing workflows. Corporate Innovation: Technology conglomerates frequently establish specialized spinouts to concentrate resources on targeted AI use cases in life sciences.
Categories
techai